Cosmetic Efficacy Peptide Raw Material Analysis Series (Part 2): Acetyl Hexapeptide-8

In the previous analysis of Palmitoyl Pentapeptide-4, we explored its mechanism of action as a "collagen signaling peptide"—by promoting the synthesis of extracellular matrix components such as collagen and elastin by fibroblasts, it plumps the skin's support structure from within, achieving anti-aging and repair. This mechanism represents a crucial approach whereby peptide raw materials combat wrinkles through "replenishment and reconstruction."

However, a comprehensive anti-wrinkle strategy must also address intervention in another key cause of wrinkle formation: dynamic lines resulting from the repeated contraction of facial expression muscles.

If  Palmitoyl Pentapeptide-4 is considered a 'reconstruction' strategy targeting the loss of skin matrix, then this issue's focus, Acetyl Hexapeptide-8, emphasizes 'regulation.' Its function is not to directly promote structural generation but to precisely regulate the intensity of neural signal transduction, thereby inhibiting excessive muscle contraction that leads to wrinkle formation at the source.

Acetyl Hexapeptide-8 (INCI Name: Acetyl Hexapeptide-8, also known as Argireline) is a synthetic peptide composed of six amino acids. Its molecular structure mimics the N-terminal fragment of the SNAP-25 protein, which is the functional domain of botulinum toxin. Its core mechanism involves acting as a competitive inhibitor, disrupting the formation of the SNARE complex on the presynaptic membrane of neurons. By occupying the binding site of SNAP-25, it effectively inhibits the excessive release of neurotransmitters (such as acetylcholine), thereby weakening muscle contraction signals, relaxing muscles, and smoothing dynamic wrinkles. This effect is reversible and non-invasive, earning it the reputation as "topical botox."

Their mechanisms are complementary, collectively forming a dual-action strategy in anti-wrinkle formulations that combines "inhibiting expression lines + promoting collagen regeneration." Next, we will systematically analyze Acetyl Hexapeptide-8, a peptide ingredient renowned for its neuromodulatory effects.

Name: Acetyl Hexapeptide-8

Also known as: Argireline

C A S ：616204-22-9

Molecular Formula: C₃₄H₆₀N₁₄O₁₂S

Molecular Weight: 888.91 g/mol

Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂

Overview: Anti-wrinkle effect. It works by blocking the transmission of signals between nerves and muscles, leading to relaxation of overactive muscles. This helps smooth dynamic wrinkles, expression lines, and other fine surface wrinkles. It is used in anti-wrinkle and moisturizing products.

Synthetic Process:

Currently, the synthesis methods for Acetyl Hexapeptide-8 include solid-phase sequential coupling. This method involves the stepwise coupling of side-chain protected amino acids to obtain the peptide-resin intermediate. While solid-phase/ liquid-phase hybrid methods exist, their complex operations make them unsuitable for large-scale production. Liquid-phase synthesis methods utilizing unprotected arginine and glutamine involve numerous reaction steps, require long production cycles, and demand high purification techniques, making them less efficient.

In contrast, solid-phase synthesis is relatively straightforward, convenient, offers high flexibility, and can be performed using fully automated solid-phase peptide synthesizers instead of manual operation, making it increasingly the mainstream method. A representative solid-phase synthesis procedure is outlined below for reference.

① Resin Pretreatment

Resin Selection: Use Rink Amide AM resin with a substitution degree of 0.6-1.2 mmol/g (loading 1 eq, mass W g).

Swelling and Washing: Add the resin to the reactor and swell it with DMF (DMF volume 2-10W mL/g), bubbling with nitrogen for 30 min. Add a deprotection solution (piperidine:DMF = 10-30:80, v/v) for deprotection over 30 min. Wash the resin with DMF 5-7 times (each wash volume 2-10W mL/g), then drain thoroughly for subsequent use.

② Amino Acid Coupling (Sequential Coupling in Order)

Coupling Sequence: Fmoc-Arg(HCl)-OH → Fmoc-Arg(HCl)-OH → Fmoc-Gln-OH → Fmoc-Met-OH → Fmoc-Glu(OtBu)-OH → Fmoc-Glu(OtBu)-OH (6 amino acids in total).

Single Coupling Step Operation (Taking the first Fmoc-Arg(HCl)-OH as an example):

Activation: Dissolve Fmoc-Arg(HCl)-OH (1.5-4 eq) and HOBt (1.5-4 eq) in DMF (volume 2-10W mL/g), pre-cool to 0-10°C. Add DIC (1.5-4 eq) and activate for 5-15 min.

Reaction: Add the activation solution to the resin reactor and react for 2-3 hours.

Washing and Deprotection: Drain the reaction solution, wash the resin with DMF 2-4 times (each wash volume 2-10W mL/g). Add the deprotection solution (as above) for deprotection (25-35 min). Wash again with DMF 5-7 times, drain thoroughly, and proceed to the next coupling step.

Note: The subsequent 5 amino acid coupling steps follow the same procedure (only replacing the corresponding Fmoc-amino acid), repeating the "Activation → Reaction → Washing → Deprotection" cycle.

③ Acetylation Modification

After all amino acids are coupled, perform acetylation: Add an acetylation solution (acetic anhydride:pyridine = 15-45:30, v/v) to the peptide-resin, and react for 0.5-1.5 hours (acetic anhydride 20 eq, pyridine 20 eq).

Washing and Drying: Wash the resin with DMF 3-5 times, then with DCM 2-4 times. Add methanol to shrink the resin, followed by vacuum drying to obtain the acetylated peptide-resin.

④ Cleavage and Crude Peptide Isolation

Cleavage: Add the peptide-resin to a cleavage cocktail (TFA:deionized water = 85-105:5, v/v; optionally add TIS, TIS:water = 2-10:5). React at 20-30°C for 1-3 hours (peptide-resin:TFA ≈ 5-15 g:95 mL).

Filtration and Precipitation: Filter the cleavage mixture. Add the filtrate to a pre-cooled (-15~-25°C) precipitant (methyl tert-butyl ether/diethyl ether, peptide-resin:precipitant ≈ 5-15 g:100 mL) to precipitate the solid.

Washing and Drying: Wash the solid precipitate 3 times with the precipitant (wash volume:peptide-resin ≈ 100 mL:5-15 g). Dry under vacuum at 15-25°C for 20-25 hours to obtain the crude Acetyl Hexapeptide-8.

⑤ Purification

Column Chromatography Purification: Use a C18 column or a modified stationary phase (e.g., silica microspheres functionalized with thiol groups and grafted with ligands like N-(benzo[D]thiazol-2-ylmethyl)acrylamide, methyl 2-acetamido-2-methoxyacetate, tert-butyl (2-acrylamidoethyl)carbamate).

Mobile Phase: A phase (0.05-0.15 wt% TFA aqueous solution), B phase (0.05-0.15 wt% TFA acetonitrile solution); gradient elution (A:B = 70-90:10-30, v/v).

Conditions: Flow rate 0.8-1.2 mL/min, injection volume 5-15 μL.

Collection and Lyophilization: Collect the target peak fractions. Lyophilize to obtain the purified Acetyl Hexapeptide-8 (purity ≥98%, high yield).

⑥ Core Advantages 

This process minimizes side reactions and impurity generation through a minimal side-chain protection strategy, and enhances purification efficiency using modified chromatographic media with porous network coatings for improved selectivity, ultimately achieving high yield and high purity Acetyl Hexapeptide-8 via solid-phase synthesis.